RE-BVS – Piemonte Repository

Sfoglia per RIVISTA
THE LANCET. ONCOLOGY
Collezione AO Cuneo

Items : 7

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. in The Lancet. Oncology / Lancet Oncol. 2023 Oct;24(10):1119-1133. doi: 10.1016/S1470-2045(23)00405-9. Epub 2023 Sep 14.

2023
AO Cuneo
AOU Città della Salute di Torino

Musto P; Boccadoro M; Gay F; Sonneveld P; Vangsted AJ; Benjamin R; Hájek R; Silkjaer T; Caers J; Zweegman S; Mancuso K; Razawy W; Tacchetti P; Offidani M; Grasso M; Giaccone L; van der Velden VHJ; Pour L; Lund T; Gadisseur A; Pietrantuono G; Roeloffzen WWH; Broijl A; Schjesvold F; Wu KL; van der Holt B; Minnema MC; van de Donk NWCJ;

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. in The Lancet. Oncology / Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14.

2023
AOU Città della Salute di Torino
AO Cuneo

Boccadoro M; Gay F; Ballanti S; Belotti A; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Grasso M; Zamagni E; Fioritoni F; Cea M; Pescosta N; Vincelli ID; Ronconi S; Pavone V; Capra A; Oddolo D; de Fabritiis P; Palmas A; Mina R; Paris L; Aquino S; Gamberi B; Rota-Scalabrini D; Musto P;

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2022 Dec;23(12):1571-1582. doi: 10.1016/S1470-2045(22)00632-5. Epub 2022 Nov 10.

2022
AO Cuneo
ASL Città di Torino

Lambertini M; Colantuoni G; Puglisi F; Montemurro F; Bighin C; Correale P; Poletti P; Mansutti M; Alicicco MG; Urracci Y; Gasparro S; Garrone O; Fabi A; Cognetti F; Vaccaro A; Nisticò C; Turletti A; Bisagni G; Rimanti A; Gravina A; De Laurentiis M; Forestieri V; Giuliano M; Blondeaux E; De Placido S; Poggio F; Boni L; Del Mastro L;

Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Oct;22(10):1458-1467. doi: 10.1016/S1470-2045(21)00352-1. Epub 2021 Sep 17.

2021
AO Cuneo
AOU Città della Salute di Torino

Bruzzi P; Montemurro F; Ballestrero A; Lambertini M; Amaducci L; Campadelli E; Arpino G; Moretti G; Tamberi S; Bighin C; Puglisi F; Barone C; Garrone O; Fabi A; Gori S; De Placido S; Urracci Y; Sanna G; Mura S; Michelotti A; Poggio F; Frassoldati A; Cognetti F; Durando A; Ponzone R; Del Mastro L; Mansutti M; Bisagni G;

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.

2021
AO Cuneo
AOU Città della Salute di Torino

Boccadoro M; Cavo M; Corradini P; Petrucci MT; Zambello R; Gamberi B; Aquino S; Palmas A; de Fabritiis P; Giuliani N; D'Agostino M; Capra A; Patriarca F; Cea M; Spadano A; Grasso M; Ballanti S; Zamagni E; Ledda A; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F;

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. in The Lancet. Oncology / Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.

2020
AOU Città della Salute di Torino
AO Cuneo

Fenocchio E; Mammoliti S; Cupini S; Roselli M; Mambrini A; Ritorto G; Clavarezza M; Carlomagno C; Di Donato S; Ronzoni M; Masi G; Tomasello G; Antonuzzo L; Corallo S; Cordio S; Moretto R; Buonadonna A; Granetto C; Murgioni S; Zaniboni A; Aprile G; Grande R; Marmorino F; Passardi A; Santini D; Tamburini E; Latiano TP; Bordonaro R; Pietrantonio F; et alii...

Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2015 Nov;16(15):1525-1536. doi: 10.1016/S1470-2045(15)00200-4. Epub 2015 Sep 28.

2015
AO Cuneo
AOU Alessandria

Bosi A; Bacigalupo A; Oldani E; Marfisi RM; Mordini N; Scimè R; Torelli GF; Corradini P; Alessandrino EP; Russo D; Nagler A; Marotta G; Carella AM; Arcese W; Terruzzi E; Saporiti G; Pini M; Risitano AM; Patriarca F; Guidi S; Pastore D; Chiusolo P; Raimondi R; Montanari M; Milone G; Santarone S; Cavattoni I; Busca A; Bruno B; et alii...